ARCHIVES

Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone

This article is from The Cancer Letter archive.

Vol. 13 No. 15 | April 10, 1987

Download PDF Visit The Full Archive

Related Articles

NCI Prepares For Intramural Program Review

June 27, 2014

Klausner Reaffirms NCI’s “No. 1 Priority” Is Funding investigator-Initiated Research

September 13, 1996

Also: NCCN Committee Reaffirms Clinical Guideline Covering Avastin for Breast Cancer Indication

July 22, 2011

FDA Lacks Resources To Deal With Onslaught Of New Cancer Drugs, Friedman Tells Agency

August 14, 1992

Panel Tells Carter Cancer Program Needs More Money

March 4, 1977

Drug Development: FDA Grants Breakthrough Therapy Designation To CTL019 in ALL

June 11, 2014